Grazyna Klupińska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Grazyna Klupińska has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Cezary Chojnacki
Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University of Lodz, 90-647 Lodz, Poland
10 shared publications - Ewa Walecka-Kapica
Department of Gastroenterology, Medical University of Lodz, 92-213 Lodz, Poland
10 shared publications - Jan Chojnacki
Department of Clinical Nutrition and Gastroenterological Diagnostics, Medical University of Lodz, 90-647 Lodz, Poland
8 shared publications Agnieszka Harasiuk
4 shared publications- Monika Pawłowicz
Medical University of Łodz, Poland: Chair of Gastroenterology
4 shared publications Krystyna Stec-Michalska
3 shared publications
Latest Publications
- Open Access
- 5 January 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (1) , 1030-1042
Melatonin and Female Hormone Secretion in Postmenopausal Overweight Women
Estrogen deficiency is considered to be the main cause of increased appetite and increased weight in postmenopausal women. In this period, reduced secretion of melatonin (MEL) was also observed. The aim of the study was to evaluate the secretion of melatonin, 17-β estradiol and follicle-stimulating hormone (FSH) in relation to body mass index (BMI) in pre- and postmenopausal women. The study included 90 women divided into three equal groups: group I (control)—women without menstrual disorders, group II—postmenopausal women without change in appetite and body weight, group III—postmenopausal women experiencing increased appetite and weight gain. In each patient, serum melatonin, 17-β-estradiol, FSH and urine a 6-sulfatoxymelatonin (aMT6s) were determined. Compared to the control group, the level of melatonin and estradiol was statistically lower. The FSH level was higher than in the groups of postmenopausal women. No significant correlation was found in all groups between the level of melatonin and the levels of estradiol and FSH. A negative correlation was found between aMT6s excretion and BMI, and a positive correlation between the level of FSH and BMI, mainly in overweight women. The obtained results indicate a significant effect of melatonin deficiency on the process of weight gain in postmenopausal women and justify its use in treatment of these disorders.
- 5 January 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (1) , 1030-1042
Open AccessMelatonin and Female Hormone Secretion in Postmenopausal Overweight Women
Estrogen deficiency is considered to be the main cause of increased appetite and increased weight in postmenopausal women. In this period, reduced secretion of melatonin (MEL) was also observed. The aim of the study was to evaluate the secretion of melatonin, 17-β estradiol and follicle-stimulating hormone (FSH) in relation to body mass index (BMI) in pre- and postmenopausal women. The study included 90 women divided into three equal groups: group I (control)—women without menstrual disorders, group II—postmenopausal women without change in appetite and body weight, group III—postmenopausal women experiencing increased appetite and weight gain. In each patient, serum melatonin, 17-β-estradiol, FSH and urine a 6-sulfatoxymelatonin (aMT6s) were determined. Compared to the control group, the level of melatonin and estradiol was statistically lower. The FSH level was higher than in the groups of postmenopausal women. No significant correlation was found in all groups between the level of melatonin and the levels of estradiol and FSH. A negative correlation was found between aMT6s excretion and BMI, and a positive correlation between the level of FSH and BMI, mainly in overweight women. The obtained results indicate a significant effect of melatonin deficiency on the process of weight gain in postmenopausal women and justify its use in treatment of these disorders.
- 1 July 2014
- Vol. 37 (217) , 35-8
[The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women].
In postmenopausal period, there occur a variety of psychosomatic symptoms in a female organism, which include deterioration of mood, anxiety, fear, sleep disorders, excessive irritability, impaired concentration and memory, overt depression with psychomotor retardation, decreased interest and life activity, decreased or increased appetite. Fluoxetine -selective serotonin reuptake inhibitor (SSRI) is used in the treatment of obesity and depression. Tianeptine--selective serotonin reuptake enhancer (SSRE) is used in the treatment of depressive episodes. Metabolic effects of prolonged tianeptine use are not well known. The aim of the study was the evaluation of the effect of long-term use of fluoxetine and tianeptine on emotional state and eating disorders in postmenopausal women. The study was conducted in two groups of 30 postmenopausal women each, aged 52-66 years. The patients took fluoxetine for 6 months at a dose of 1 x 20 mg in the morning (group I) or tianeptine at a dose of 3 x 12.5 mg/daily (group II). Follow-up visits were conducted at 2, 4, 8, 12, 16 and 20 weeks. At week 24, extended tests were performed, including the assessment of the level of anxiety (Hamilton Anxiety Rating Scale-HARS) and depression (Beck Depression Inventory-BDI), the body mass index (BMI) and the waist/ hip ratio (WHR), which were compared with the corresponding results prior to the treatment with fluoxetine and tianeptine. After 6 months, in the group receiving fluoxetine, the reduction of the level of anxiety was obtained from 22.92 +/- 4.08 points to 12.36 +/- 2.43 points (p < 0.001) and a decrease in depression symptoms from 19.28 +/- 2.53 points to 10, 44 +/- 2.02 points (p < 0.001), but no reduction in body mass index was obtained -respectively 29.4 +/- 3.54 and 29.7 +/- 3.26 (p > 0.05) nor in the waist/ hip ratio--respectively 0.886 +/- 0.03 and 0.879 +/- 0.03 (p > 0.05). After 6 months, in the group receiving tianeptine, the reduction of the level of anxiety was achieved from 22.00 +/- 3.35 points to 15.20 +/- 3.42 points (p < 0.001) and a decrease in depression symptoms from 18.80 +/- 2.45 points to 14,16 +/- 4.06 points (p < 0.001), whereas no reduction in body mass index was obtained- respectively 27.7 +/- 2.81 and 27.4 +/- 2.65 (p > 0.05), even though slightly reduced waist/ hip ratio--from 0.877 +/- 0.03 to 0.863 +/- 0.03 (p < 0.05) was observed. Fluoxetine was more effective than tianeptine in the reduction of the level of anxiety (chi2 = 17.459, p < 0.01) as well as the reduction in the symptoms of depression (chi2 = 17.469, p < 0.01). Both tianeptine and fluoxetine are effective in the treatment of emotional disturbances in postmenopausal women. Both drugs may decrease appetite but long-term treatment does not alter body weight to the desired extent and they do not match the standards as monotherapy for obesity.
- 1 July 2014
- Vol. 37 (217) , 35-8
[The effect of fluoxetine and tianeptine on emotional and eating disorders in postmenopausal women].
In postmenopausal period, there occur a variety of psychosomatic symptoms in a female organism, which include deterioration of mood, anxiety, fear, sleep disorders, excessive irritability, impaired concentration and memory, overt depression with psychomotor retardation, decreased interest and life activity, decreased or increased appetite. Fluoxetine -selective serotonin reuptake inhibitor (SSRI) is used in the treatment of obesity and depression. Tianeptine--selective serotonin reuptake enhancer (SSRE) is used in the treatment of depressive episodes. Metabolic effects of prolonged tianeptine use are not well known. The aim of the study was the evaluation of the effect of long-term use of fluoxetine and tianeptine on emotional state and eating disorders in postmenopausal women. The study was conducted in two groups of 30 postmenopausal women each, aged 52-66 years. The patients took fluoxetine for 6 months at a dose of 1 x 20 mg in the morning (group I) or tianeptine at a dose of 3 x 12.5 mg/daily (group II). Follow-up visits were conducted at 2, 4, 8, 12, 16 and 20 weeks. At week 24, extended tests were performed, including the assessment of the level of anxiety (Hamilton Anxiety Rating Scale-HARS) and depression (Beck Depression Inventory-BDI), the body mass index (BMI) and the waist/ hip ratio (WHR), which were compared with the corresponding results prior to the treatment with fluoxetine and tianeptine. After 6 months, in the group receiving fluoxetine, the reduction of the level of anxiety was obtained from 22.92 +/- 4.08 points to 12.36 +/- 2.43 points (p < 0.001) and a decrease in depression symptoms from 19.28 +/- 2.53 points to 10, 44 +/- 2.02 points (p < 0.001), but no reduction in body mass index was obtained -respectively 29.4 +/- 3.54 and 29.7 +/- 3.26 (p > 0.05) nor in the waist/ hip ratio--respectively 0.886 +/- 0.03 and 0.879 +/- 0.03 (p > 0.05). After 6 months, in the group receiving tianeptine, the reduction of the level of anxiety was achieved from 22.00 +/- 3.35 points to 15.20 +/- 3.42 points (p < 0.001) and a decrease in depression symptoms from 18.80 +/- 2.45 points to 14,16 +/- 4.06 points (p < 0.001), whereas no reduction in body mass index was obtained- respectively 27.7 +/- 2.81 and 27.4 +/- 2.65 (p > 0.05), even though slightly reduced waist/ hip ratio--from 0.877 +/- 0.03 to 0.863 +/- 0.03 (p < 0.05) was observed. Fluoxetine was more effective than tianeptine in the reduction of the level of anxiety (chi2 = 17.459, p < 0.01) as well as the reduction in the symptoms of depression (chi2 = 17.469, p < 0.01). Both tianeptine and fluoxetine are effective in the treatment of emotional disturbances in postmenopausal women. Both drugs may decrease appetite but long-term treatment does not alter body weight to the desired extent and they do not match the standards as monotherapy for obesity.
- 1 July 2014
- Vol. 37 (217) , 39-42
[Efficacy of sulpiride and itopride in the treatment of functional dyspepsia in women with emotional and eating disorders].
Functional dyspepsia is often accompanied by emotional disturbances, especially in postmenopausal women. Impaired homeostasis of the dopaminergic system maybe one of the common pathogenetic factors. The aim of the study was to assess the effect of drugs which block dopamine D2 receptors on psychosomatic condition in postmenopausal women. The study was conducted in a group of 60 women, aged 53-61 years, with postprandial distress syndrome (PDS) that met the Rome Criteria III. The severity of dyspeptic symptoms was determined statistically using a 10-point Visual Analogue Scale (VAS). The emotional state was estimated with the Hamilton Anxiety Rating Scale (HARS) and the Beck Depression Inventory (BDI), whereas the body mass index (BMI) was the indicator of the nutritional status. Sulpiride (2 x 50 mg) was administered to 30 women for 16 weeks and itopride (2 x 50 mg) to 30 others. After sulpiride and itopride treatment equal decrease of dyspeptic symptoms was observed, respectively from 9.08 to 4.76 pts and from 9.02 to 4.64 pts. Significant reduction in the level of anxiety (p < 0.001) and depression (p < 0.01) was obtained in both groups, slightly higher after sulpiride. However, no significant change in BMI was found. Sulpiride and itopride are effective in the treatment of dyspepsia in the form of postprandial distress syndrome. These drugs in the several-month treatment have no significant effect on body weight.
- 1 July 2014
- Vol. 37 (217) , 39-42
[Efficacy of sulpiride and itopride in the treatment of functional dyspepsia in women with emotional and eating disorders].
Functional dyspepsia is often accompanied by emotional disturbances, especially in postmenopausal women. Impaired homeostasis of the dopaminergic system maybe one of the common pathogenetic factors. The aim of the study was to assess the effect of drugs which block dopamine D2 receptors on psychosomatic condition in postmenopausal women. The study was conducted in a group of 60 women, aged 53-61 years, with postprandial distress syndrome (PDS) that met the Rome Criteria III. The severity of dyspeptic symptoms was determined statistically using a 10-point Visual Analogue Scale (VAS). The emotional state was estimated with the Hamilton Anxiety Rating Scale (HARS) and the Beck Depression Inventory (BDI), whereas the body mass index (BMI) was the indicator of the nutritional status. Sulpiride (2 x 50 mg) was administered to 30 women for 16 weeks and itopride (2 x 50 mg) to 30 others. After sulpiride and itopride treatment equal decrease of dyspeptic symptoms was observed, respectively from 9.08 to 4.76 pts and from 9.02 to 4.64 pts. Significant reduction in the level of anxiety (p < 0.001) and depression (p < 0.01) was obtained in both groups, slightly higher after sulpiride. However, no significant change in BMI was found. Sulpiride and itopride are effective in the treatment of dyspepsia in the form of postprandial distress syndrome. These drugs in the several-month treatment have no significant effect on body weight.
- 1 May 2014
- Vol. 36 (215) , 307-10
[Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome].
Irritable bowel syndrome (IBS) is one of the most common reason for gastroenterology consultations. The diverse in symptomatology of the disease comes from its rich etiopathogenesis. Recently studies talk about infectious etiology of IBS and because of that it is necessary to expand its diagnostics by small intestinal bacterial overgrowth (SIBO) test. The aim of this study was to evaluate the prevalence of small intestinal bacterial overgrowth in patients with constipation (IBS-C) and diarrhea (IBS-D) irritable bowel syndrome with regard to nutrition. The study involved 46 subjects (33 women and 13 men) in average age of 44 years, which were divided into two groups: diarrhea and constipation IBS. All patients underwent hydrogen breath test studying bacterial overgrowth in the small intestine. In addition, each person had fulfilled a feeding questionnaire. Student's t-test, Pearson test. It has been shown that there is no statistical significances between the prevalence of SIBO in form of diarrheal IBS and constipation IBS and gender. Average value of increments of hydrogen in breath during the test was higher in IBS-C in comparison with IBS-D, which was the highest in the intestine bacterial overgrowth in patients with IBS-C. STATISTICAL ANALYSIS showed that there is no relationship between the type and frequency of consumption of milk, meat, fruit and vegetables, sweets and coffee and the prevalence of SIBO in form of diarrhea and constipation IBS. The occurrence of constipation or diarrhea irritable bowel syndrome is not related to gender. SIBO is more common in patients with IBS-C than in IBS-D group. There is no relationship between the type of food consumed and the amount of SIBO in people with IBS. Type of food intake do not affect the status of the intestinal flora of people with IBS.
- 1 May 2014
- Vol. 36 (215) , 307-10
[Estimation of small intestinal bacterial overgrowth in patients with constipation and diarrhea irritable bowel syndrome].
Irritable bowel syndrome (IBS) is one of the most common reason for gastroenterology consultations. The diverse in symptomatology of the disease comes from its rich etiopathogenesis. Recently studies talk about infectious etiology of IBS and because of that it is necessary to expand its diagnostics by small intestinal bacterial overgrowth (SIBO) test. The aim of this study was to evaluate the prevalence of small intestinal bacterial overgrowth in patients with constipation (IBS-C) and diarrhea (IBS-D) irritable bowel syndrome with regard to nutrition. The study involved 46 subjects (33 women and 13 men) in average age of 44 years, which were divided into two groups: diarrhea and constipation IBS. All patients underwent hydrogen breath test studying bacterial overgrowth in the small intestine. In addition, each person had fulfilled a feeding questionnaire. Student's t-test, Pearson test. It has been shown that there is no statistical significances between the prevalence of SIBO in form of diarrheal IBS and constipation IBS and gender. Average value of increments of hydrogen in breath during the test was higher in IBS-C in comparison with IBS-D, which was the highest in the intestine bacterial overgrowth in patients with IBS-C. STATISTICAL ANALYSIS showed that there is no relationship between the type and frequency of consumption of milk, meat, fruit and vegetables, sweets and coffee and the prevalence of SIBO in form of diarrhea and constipation IBS. The occurrence of constipation or diarrhea irritable bowel syndrome is not related to gender. SIBO is more common in patients with IBS-C than in IBS-D group. There is no relationship between the type of food consumed and the amount of SIBO in people with IBS. Type of food intake do not affect the status of the intestinal flora of people with IBS.
- Open Access
- 14 June 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (6) , 12550-12562
Does Melatonin Homeostasis Play a Role in Continuous Epigastric Pain Syndrome?
Two clinical forms of functional dyspepsia (FD) are listed in the Rome III criteria: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), differing in the recurrence of ailments depending on the diet. Continuous EPS (CEPS) is observed in some EPS patients, also at night, but its cause is still unknown. We showed previously that melatonin (MEL) homeostasis may be associated with FD. In the present work we evaluated selected components of melatonin homeostasis in patients with CEPS. The study included 30 patients with CEPS, 21 women and nine men, aged 21–49 years and 30 control subjects (EPS excluded); organic and mental diseases, as well as Helicobacter pylori infection, were excluded in both groups. The average severity of abdominal pain in the last three months was estimated in a 10-point scale (Visual Analog Scale). The levels of mRNA expression of arylalkylamine-N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT), the main components of MEL homeostasis, were determined in gastric mucosa with real time PCR. The fasting serum level of MEL (at 09:00 a.m.) and circadian urine excretion of 6-sulfatoxymelatonin (6-HMS) were determined with ELISA. AANAT expression in antral mucosa of control subjects was 1.76 ± 0.41, in the gastric body 1.35 ± 0.38, and in the dyspeptic group 1.42 ± 0.38 (p < 0.05) and 0.92 ± 0.55 (p < 0.05), respectively. HIOMT expression in the control was 2.05 ± 0.70 in the antrum and 1.57 ± 0.69 in the body and in the CEPS group, it was: 1.51 ± 0.57 (p < 0.05) and 0.74 ± 0.31 (p < 0.001), respectively. MEL concentration (pg/mL) was 9.41 ± 3.09 in the control group and 5.62 ± 1.34 (p < 0.01) in the CEPS group. Urinary 6-HMS excretion (μg/24 h) was 11.40 ± 4.46 in the controls and 7.68 ± 2.88 (p < 0.05) in the CEPS. Moreover, a negative correlation was found between the tested parameters and severity of epigastric pain. These results indicate that patients with CEPS may display low level of AANAT and HIOMT expression in gastric mucosa, resulting in decreased MEL synthesis.
- 14 June 2013
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (6) , 12550-12562
Open AccessDoes Melatonin Homeostasis Play a Role in Continuous Epigastric Pain Syndrome?
Two clinical forms of functional dyspepsia (FD) are listed in the Rome III criteria: postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), differing in the recurrence of ailments depending on the diet. Continuous EPS (CEPS) is observed in some EPS patients, also at night, but its cause is still unknown. We showed previously that melatonin (MEL) homeostasis may be associated with FD. In the present work we evaluated selected components of melatonin homeostasis in patients with CEPS. The study included 30 patients with CEPS, 21 women and nine men, aged 21–49 years and 30 control subjects (EPS excluded); organic and mental diseases, as well as Helicobacter pylori infection, were excluded in both groups. The average severity of abdominal pain in the last three months was estimated in a 10-point scale (Visual Analog Scale). The levels of mRNA expression of arylalkylamine-N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT), the main components of MEL homeostasis, were determined in gastric mucosa with real time PCR. The fasting serum level of MEL (at 09:00 a.m.) and circadian urine excretion of 6-sulfatoxymelatonin (6-HMS) were determined with ELISA. AANAT expression in antral mucosa of control subjects was 1.76 ± 0.41, in the gastric body 1.35 ± 0.38, and in the dyspeptic group 1.42 ± 0.38 (p < 0.05) and 0.92 ± 0.55 (p < 0.05), respectively. HIOMT expression in the control was 2.05 ± 0.70 in the antrum and 1.57 ± 0.69 in the body and in the CEPS group, it was: 1.51 ± 0.57 (p < 0.05) and 0.74 ± 0.31 (p < 0.001), respectively. MEL concentration (pg/mL) was 9.41 ± 3.09 in the control group and 5.62 ± 1.34 (p < 0.01) in the CEPS group. Urinary 6-HMS excretion (μg/24 h) was 11.40 ± 4.46 in the controls and 7.68 ± 2.88 (p < 0.05) in the CEPS. Moreover, a negative correlation was found between the tested parameters and severity of epigastric pain. These results indicate that patients with CEPS may display low level of AANAT and HIOMT expression in gastric mucosa, resulting in decreased MEL synthesis.
- 1 January 2013
- Vol. 64 (2) , 114-20
Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women.
Melatonin (MEL) exerts beneficial effects on the gut partly by myorelaxative properties upon the smooth muscle. Its secretion decreases with age, particularly in postmenopausal women. This study was aimed at evaluating the effect of MEL on the symptoms of irritable bowel syndrome (IBS) in this group of patients. The investigations were carried out in 80 postmenopausal women, aged 48-65 years, divided into two equal groups, diagnosed according to Rome Criteria III: i.e. patients with IBS with constipation predominant (IBS-C), and patients with IBS with diarrhoea predominant (IBS-D). The control group (C) included healthy women aged 46-65 years. In all subjects, 6-sulfatoxymelatonin (6-HMS) concentration urine was measured using ELISA assay. Patients in both groups over the course of six months were given melatonin (at a dose of 3 mg fasting and 5 mg at bedtime) or a placebo (double blind trial). Disease activity was evaluated after two, four and six months, using a ten-point scale to assess the main somatic symptoms: visceral pain, abdominal bloating, etc. The amounts of 6-HMS urine excretion (μg/24 h) were: C 11.4 ± 3.0, IBS-C 10.2 ± 3.2, IBS-D 14.0 ± 6.3 (p 〈 0.05). Correlation between values of symptoms score and contrary excretion of 6-HMS: IBS-C r = -0.714, IBS-D r = 0.409. After six months in the IBS-C group, the intensity of visceral pain and abdominal bloating had decreased in 70% of patients (p 〈 0.01) and constipation in 50% of patients (p 〈 0.05). Beneficial changes in the IBS-D group were noted in 45% of patients, but this was not better compared to the placebo. Melatonin can be used as part of the treatment of IBS, particularly in patients with constipation-predominant IBS.
- 1 January 2013
- Vol. 64 (2) , 114-20
Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women.
Melatonin (MEL) exerts beneficial effects on the gut partly by myorelaxative properties upon the smooth muscle. Its secretion decreases with age, particularly in postmenopausal women. This study was aimed at evaluating the effect of MEL on the symptoms of irritable bowel syndrome (IBS) in this group of patients. The investigations were carried out in 80 postmenopausal women, aged 48-65 years, divided into two equal groups, diagnosed according to Rome Criteria III: i.e. patients with IBS with constipation predominant (IBS-C), and patients with IBS with diarrhoea predominant (IBS-D). The control group (C) included healthy women aged 46-65 years. In all subjects, 6-sulfatoxymelatonin (6-HMS) concentration urine was measured using ELISA assay. Patients in both groups over the course of six months were given melatonin (at a dose of 3 mg fasting and 5 mg at bedtime) or a placebo (double blind trial). Disease activity was evaluated after two, four and six months, using a ten-point scale to assess the main somatic symptoms: visceral pain, abdominal bloating, etc. The amounts of 6-HMS urine excretion (μg/24 h) were: C 11.4 ± 3.0, IBS-C 10.2 ± 3.2, IBS-D 14.0 ± 6.3 (p 〈 0.05). Correlation between values of symptoms score and contrary excretion of 6-HMS: IBS-C r = -0.714, IBS-D r = 0.409. After six months in the IBS-C group, the intensity of visceral pain and abdominal bloating had decreased in 70% of patients (p 〈 0.01) and constipation in 50% of patients (p 〈 0.05). Beneficial changes in the IBS-D group were noted in 45% of patients, but this was not better compared to the placebo. Melatonin can be used as part of the treatment of IBS, particularly in patients with constipation-predominant IBS.
- 1 August 2011
- Vol. 31 (182) , 92-6
[Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission].
In order to maintain ulcerative colitis (UC) in remission, chronic use of aminosalicylates is recommended. All patients have a fear of the recurrence of symptoms, which makes their mental state and quality of life worse. Because of this a number of patients are recommended to use different sorts of anxiolytic drugs and antidepressants. Evaluation of the influence of tianeptine (selective serotonin reuptake enhancer) on the mental and somatic status in the group of patients. The research was conducted in two groups of thirty patients, with benign form of ulcerative colitis in remission, aged 24-46 years. Patients, during a period of 12 months, were given aminosalicylates in a daily doses 2 x 1.0 g and tianeptine in a doses 3 x 12.5 mg (group I) or placebo (group II). During the treatment every three months anxiety (Hamilton Anxiety Rating Scale-HARS), depression (Back Depression Inventory-BDI), The Mayo Clinic Disease Activity Index (MCDAI), hemoglobin and C-reactive protein (CRP) level were evaluated. After 12 months in a group of patients who took tianeptine decrease in anxiety (from 20.35 +/- 4.03 to 12.65 +/- 3.78 points) and depression (from 19.95 +/- 4.49 points to 9.60 +/- 2.76 points) was obtained; difference compared with placebo was statistically significant (p < 0.01). At the same time significant decrease compared with placebo (p < 0.05) of disease activity index (respectively 3.05 +/- 1.36 and 4.65 +/- 1.69), insignificantly lower level of CRP (7.00 5.65 and 9.41 +/- 10.12) and higher level of hemoglobin (11.93 +/- 0.83 and 11.0 +/- 0.70) was observed. Tianeptine has a positive influence on mental and somatic status of patients with UC. Results give the support for tianeptine apllication in UC as adjuvant drug.
- 1 August 2011
- Vol. 31 (182) , 92-6
[Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission].
In order to maintain ulcerative colitis (UC) in remission, chronic use of aminosalicylates is recommended. All patients have a fear of the recurrence of symptoms, which makes their mental state and quality of life worse. Because of this a number of patients are recommended to use different sorts of anxiolytic drugs and antidepressants. Evaluation of the influence of tianeptine (selective serotonin reuptake enhancer) on the mental and somatic status in the group of patients. The research was conducted in two groups of thirty patients, with benign form of ulcerative colitis in remission, aged 24-46 years. Patients, during a period of 12 months, were given aminosalicylates in a daily doses 2 x 1.0 g and tianeptine in a doses 3 x 12.5 mg (group I) or placebo (group II). During the treatment every three months anxiety (Hamilton Anxiety Rating Scale-HARS), depression (Back Depression Inventory-BDI), The Mayo Clinic Disease Activity Index (MCDAI), hemoglobin and C-reactive protein (CRP) level were evaluated. After 12 months in a group of patients who took tianeptine decrease in anxiety (from 20.35 +/- 4.03 to 12.65 +/- 3.78 points) and depression (from 19.95 +/- 4.49 points to 9.60 +/- 2.76 points) was obtained; difference compared with placebo was statistically significant (p < 0.01). At the same time significant decrease compared with placebo (p < 0.05) of disease activity index (respectively 3.05 +/- 1.36 and 4.65 +/- 1.69), insignificantly lower level of CRP (7.00 5.65 and 9.41 +/- 10.12) and higher level of hemoglobin (11.93 +/- 0.83 and 11.0 +/- 0.70) was observed. Tianeptine has a positive influence on mental and somatic status of patients with UC. Results give the support for tianeptine apllication in UC as adjuvant drug.
- Open Access
- 1 January 2010
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 5, 285-291
Diagnostic value of measuring serum serotonin and urinary 5-hydroxyindoleacetic acid concentration in the diagnosis of functional dyspepsia
Wstęp : Patogeneza dyspepsji czynnościowej jest niedostatecznie poznana. Rozpoznanie ustalane jest na podstawie objawów subiektywnych, niemniej ciągle poszukuje się przyczyn i obiektywnych wykładników, które ułatwiłyby diagnostykę i wyjaśniły różnorodność objawów klinicznych...
- 1 January 2010
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 5, 285-291
Open AccessDiagnostic value of measuring serum serotonin and urinary 5-hydroxyindoleacetic acid concentration in the diagnosis of functional dyspepsia
Wstęp : Patogeneza dyspepsji czynnościowej jest niedostatecznie poznana. Rozpoznanie ustalane jest na podstawie objawów subiektywnych, niemniej ciągle poszukuje się przyczyn i obiektywnych wykładników, które ułatwiłyby diagnostykę i wyjaśniły różnorodność objawów klinicznych...
- 1 May 2009
- Vol. 26 (155) , 362-5
[Gastrin secretion in patients with functional dyspepsia].
The pathogenesis of functional dyspepsia is very complicated and its etiology is still not clear. One of the supposed pathophysiological mechanisms are disturbences of gastric acid secretion and gastric motility. Recently, it has been recognized, that in the pathogenesis of above disturbances may play a role enterohormones, like gastrin. To establish if in patients with functional dyspepsia the level of gastrin concentration changes and wheather it correlates with type and grade of symptom's intensity. The study included 50 subjects between of 20 to 54 years with diagnosed functional dyspepsia (according to the Rome III Criteria). The study group was divided into two subgroups: group I--25 subjects with Epigastric Pain Syndrome--EPS and group II--25 subjects with Postprandial Distress Syndrome--PDS. Control group comprised 20 healthy subjects (without any clinical or morphological symptoms of digestive tract disease). In each patient due to gastrointestinal tract organic disease exclusion the gastroscopy, histological examination of gastric mucosa, ultrasonography of abdomen and laboratory tests were performed. H. pylori infection was detected using fast urea test (CLO-test), confirmed by histopathological examination (stained Giemsa method) and non-invasive urea breath test (UBT-13C) using mass spectrophotometer FANci 2 (Fisher Analyser Instrumente GmbH). In each patient the level of gastrin concentration in blood serum, in fasting state, was determined, based on ELISA method considering the length of the weave lamda=430 nm. The study group was also divided into 3 subgroups, using 10-points scale of symptom's intensity: --grade 1--mild (1-3 points); --grade 2--moderate (4-6 points); --grade 3--severe (7-10 points). The concentration of gastrin in blood serum in healthy subjects was 2.4 +/- 1.23 pmol/L. In patients with functional dyspepsia was significantly higher; in patients with Epigastric Pain Syndrome--7.51 +/- 2.46 pmol/L (p < 0.05), in patients with Postprandial Distress Syndrome - 6,92 +/- 2.18 pmol/L (p < 0.05). There were no significant differences in dependence on pain's intensity in EPS--the concentrations in subgroups 1, 2 and 3 were: 7.36 +/- 1.4 pmol/L, 7.53 +/- 2.43 pmol/L and 7.64 +/- 2.55 pmol/L. The gastrin concentration in PDS in dependence on symptom's intensity in subgroup 1 was 6.34 +/- 1.2 pmol/L, in subgroups 2 and 3 were higher: 6.99 +/- 2.31 pmol/L and 7.42 +/- 2.2 pmol/L, but the differences were not statistically significant. In patients with functional dyspepsia, infected with H. pylori the gastrin concentration was significantly higher and was 15.28 +/- 5.3 pmol/L (p < 0.05). There were no significant differences in dependence on type of dyspepsia. The gastrin concentration in blood serum in fasting state in patients with functional dyspepsia is higher than in control subjects, both in patients with Epigastric Pain Syndrome--EPS as well as with Postprandial Distress Syndrome--PDS. The grade of symptom's intensity does not correlate with increase of gastrin concentration.
- 1 May 2009
- Vol. 26 (155) , 362-5
[Gastrin secretion in patients with functional dyspepsia].
The pathogenesis of functional dyspepsia is very complicated and its etiology is still not clear. One of the supposed pathophysiological mechanisms are disturbences of gastric acid secretion and gastric motility. Recently, it has been recognized, that in the pathogenesis of above disturbances may play a role enterohormones, like gastrin. To establish if in patients with functional dyspepsia the level of gastrin concentration changes and wheather it correlates with type and grade of symptom's intensity. The study included 50 subjects between of 20 to 54 years with diagnosed functional dyspepsia (according to the Rome III Criteria). The study group was divided into two subgroups: group I--25 subjects with Epigastric Pain Syndrome--EPS and group II--25 subjects with Postprandial Distress Syndrome--PDS. Control group comprised 20 healthy subjects (without any clinical or morphological symptoms of digestive tract disease). In each patient due to gastrointestinal tract organic disease exclusion the gastroscopy, histological examination of gastric mucosa, ultrasonography of abdomen and laboratory tests were performed. H. pylori infection was detected using fast urea test (CLO-test), confirmed by histopathological examination (stained Giemsa method) and non-invasive urea breath test (UBT-13C) using mass spectrophotometer FANci 2 (Fisher Analyser Instrumente GmbH). In each patient the level of gastrin concentration in blood serum, in fasting state, was determined, based on ELISA method considering the length of the weave lamda=430 nm. The study group was also divided into 3 subgroups, using 10-points scale of symptom's intensity: --grade 1--mild (1-3 points); --grade 2--moderate (4-6 points); --grade 3--severe (7-10 points). The concentration of gastrin in blood serum in healthy subjects was 2.4 +/- 1.23 pmol/L. In patients with functional dyspepsia was significantly higher; in patients with Epigastric Pain Syndrome--7.51 +/- 2.46 pmol/L (p < 0.05), in patients with Postprandial Distress Syndrome - 6,92 +/- 2.18 pmol/L (p < 0.05). There were no significant differences in dependence on pain's intensity in EPS--the concentrations in subgroups 1, 2 and 3 were: 7.36 +/- 1.4 pmol/L, 7.53 +/- 2.43 pmol/L and 7.64 +/- 2.55 pmol/L. The gastrin concentration in PDS in dependence on symptom's intensity in subgroup 1 was 6.34 +/- 1.2 pmol/L, in subgroups 2 and 3 were higher: 6.99 +/- 2.31 pmol/L and 7.42 +/- 2.2 pmol/L, but the differences were not statistically significant. In patients with functional dyspepsia, infected with H. pylori the gastrin concentration was significantly higher and was 15.28 +/- 5.3 pmol/L (p < 0.05). There were no significant differences in dependence on type of dyspepsia. The gastrin concentration in blood serum in fasting state in patients with functional dyspepsia is higher than in control subjects, both in patients with Epigastric Pain Syndrome--EPS as well as with Postprandial Distress Syndrome--PDS. The grade of symptom's intensity does not correlate with increase of gastrin concentration.
- 1 May 2009
- Vol. 26 (155) , 366-9
[The effect of melatonin on oxidative DNA damage in gastric mucosa cells of patients with functional dyspepsia].
The oxidative damage of DNA expresses severe cell lesion. The excess of oxygen free radicals is one of the causes of this type of disorders. Such a situation could occur in the course of H. pylori infection. Melatonin is a natural and very active antioxidant compound. To establish weather an administration of melatonin decreases oxidative DNA damage in gastric mucosa cells. The study comprised 80 subjects, divided into two groups: group I (n=30)--patients with functional dyspepsia, H. pylori positive (+), with Epigastric Pain Syndrome, with H. pylori infection; group II (n=30)--patients H. pylori negative (-) with the same form of functional dyspepsia. The control group (0) comprised 20 subjects, aged 21-60 years. In healthy subjects, non-infected with H. pylori the level of oxidative DNA damage in gastric mucosa cells was 6.95 +/- 2.98. In both study groups the percentage of oxidative DNA damage was respectively: 12.12 +/- 5.48% and 13.62 +/- 4.58% (p < 0.001). The differences in the results obtained in both study groups, that is H. pylori (+) and H. pylori (-) were similar (p > 0.05). In group of patients with functional dyspepsia and H. pylori infection the level of oxidative DNA damage in gastrocytes was 12.12 +/- 5.48%, and after 3 months administration of melatonin it decreased to the value 10.55 +/- 0.63% (p < 0.001). In patients with functional dyspepsia, without H. pylori infection the decrease of the level of oxidative DNA damages after melatonin administration was statistically significant and it was respectively: 13.62 +/- 4.58% (p < 0.001). In functional dyspepsia, especially with coexisting H. pylori infection the oxidative DNA damage in gastric mucosa cells is observed. The melatonin administration changes the above mentioned oxidative DNA damage significantly.
- 1 May 2009
- Vol. 26 (155) , 366-9
[The effect of melatonin on oxidative DNA damage in gastric mucosa cells of patients with functional dyspepsia].
The oxidative damage of DNA expresses severe cell lesion. The excess of oxygen free radicals is one of the causes of this type of disorders. Such a situation could occur in the course of H. pylori infection. Melatonin is a natural and very active antioxidant compound. To establish weather an administration of melatonin decreases oxidative DNA damage in gastric mucosa cells. The study comprised 80 subjects, divided into two groups: group I (n=30)--patients with functional dyspepsia, H. pylori positive (+), with Epigastric Pain Syndrome, with H. pylori infection; group II (n=30)--patients H. pylori negative (-) with the same form of functional dyspepsia. The control group (0) comprised 20 subjects, aged 21-60 years. In healthy subjects, non-infected with H. pylori the level of oxidative DNA damage in gastric mucosa cells was 6.95 +/- 2.98. In both study groups the percentage of oxidative DNA damage was respectively: 12.12 +/- 5.48% and 13.62 +/- 4.58% (p < 0.001). The differences in the results obtained in both study groups, that is H. pylori (+) and H. pylori (-) were similar (p > 0.05). In group of patients with functional dyspepsia and H. pylori infection the level of oxidative DNA damage in gastrocytes was 12.12 +/- 5.48%, and after 3 months administration of melatonin it decreased to the value 10.55 +/- 0.63% (p < 0.001). In patients with functional dyspepsia, without H. pylori infection the decrease of the level of oxidative DNA damages after melatonin administration was statistically significant and it was respectively: 13.62 +/- 4.58% (p < 0.001). In functional dyspepsia, especially with coexisting H. pylori infection the oxidative DNA damage in gastric mucosa cells is observed. The melatonin administration changes the above mentioned oxidative DNA damage significantly.